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Abstract
Plasma neuronal exosomal levels of pathogenic Alzheimer’s disease (AD) proteins, cellular survival factors, and lysosomal proteins distinguish AD patients
from control subjects, but changes in these exosomal proteins associated with
normal aging have not been described for cognitively intact subjects. Plasma
neuronal exosomal levels of P-T181-tau, P-S396-tau, Ab1-42, cathepsin D,
repressor element 1-silencing transcription factor, and neurogranin were quantified longitudinally in cognitively intact older adults using two samples collected
at 3- to 11-year intervals. Except for P-S396-tau, exosomal protein levels changed significantly with aging, but were largely outside the range observed in AD
patients.
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Background
Blood-based biomarkers of Alzheimer’s disease (AD) are
needed given high costs and invasiveness of most available
biomarker technologies, including neuroimaging and
quantification of analytes in cerebrospinal fluid (CSF).1
Exosomes are released into the blood from a variety of
cells, including neurons.2 Exosomes have been shown to
play a role in neuronal development and regeneration,3
and they have been implicated in the transport of pathogenic proteins in the brain and in the progression of neurodegenerative diseases.4
Recent studies showed that neuronally derived plasma
exosomal protein levels of b-amyloid1-42 (Ab1-42) and tau

proteins (P-T181-tau and P-S396-tau) were increased
both in AD patients and in cognitively intact subjects
(CIS) who transitioned to AD 2–10 years later compared
to controls.5 Similarly, neuronally protective repressor element 1-silencing transcription factor (REST) was
decreased in both AD patients and in CIS who eventually
transitioned to AD relative to controls.6 Autolysosomal
proteins, including cathepsin D, were higher both in AD
patients and in CIS who eventually transitioned to AD
relative to controls.7
Longitudinal studies of these neuronally derived plasma
exosome proteins in CIS are needed as an appropriate
framework for interpretation of elevated values. Additionally, neurogranin, a postsynaptic protein associated with
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synapse loss, is reduced in the brains of AD patients,8 but
is increased in CSF9,10 of AD patients compared to controls. Here, we examine levels of Ab1-42, P-T181-tau,
P-S396-tau, REST, cathepsin D, and, for the first time,
neurogranin, in CIS followed at the University of Kentucky Alzheimer’s Disease Center (UK-ADC) in order to
assess aging effects on the levels of these neuronally
derived exosomal proteins.

Methods
Participant characterization, study design,
and blood sampling technique
We studied plasma and CSF samples from 20 volunteers
from the UK-ADC longitudinal cohort.11 All volunteers
were at least age 60 at UK-ADC enrollment. Volunteers
were followed annually with in-person examinations,
including neurocognitive assessment, physical exam, medical history, and neurological exam.
CIS provided blood at annual visits. Blood was centrifuged to yield platelet-free plasma and stored in
2.0-mL self-standing polypropylene tubes at
80°C.
Plasma samples were collected from November 2011 to
August 2013 (“second draw”) from participants in a biomarker study, and each was paired with a sample collected from the same participant at least 3 years earlier
(“first draw”) in order to assess longitudinal protein
changes in CIS. The CIS in this study also provided CSF
at the second draw. Two participants had no available
earlier first draw. The UK Institutional Review Board
approved all research procedures; participants provided
written informed consent.

CSF collection and measurement
Lumbar CSF was drawn using a 20-gauge needle the morning after fasting since midnight and was maintained in single use 0.5-mL aliquots in polypropylene storage tubes in a
80°C freezer. Briefly, CSF was collected into 15-mL sterile polypropylene collection tubes and transferred into
storage tubes without any centrifugation step. CSF was
batch shipped overnight to the Biomarker Research laboratory at the University of Pennsylvania Medical Center on
dry ice. Upon receipt the samples were transferred to a
80°C freezer and maintained at this temperature until
the day of analysis. Ab1-42, total tau, and P-T181-tau were
measured using the multiplex xMAP Luminex platform
(Luminex Corp, Austin, TX) with Fujirebio (INNO-BIA
AlzBio3; Ghent, Belgium; for research use–only reagents)
immunoassay kit–based reagents. The capture and detection antibodies for Ab1-42 were 4D7A3 and 3D6, respectively.12 CSF analytes were assayed without dilution.

400

E. L. Abner et al.

Isolation of exosomes from plasma for
extraction and ELISA quantification of
exosome proteins
Samples were relabeled prior to analysis to blind the laboratory. One-fourth ml of plasma was incubated with
thromboplastin-D (Fisher Scientific, Inc., Hanover Park,
IL) followed by addition of calcium- and magnesium-free
Dulbecco’s balanced salt solution with protease inhibitor
cocktail (Roche Applied Sciences, Inc., Indianapolis, IN)
and phosphatase inhibitor cocktail (Pierce Halt, Thermo
Scientific, Inc., Rockford, IL) as described earlier.5,6 After
centrifugation at 3000g for 20 min at room temperature,
supernatants were incubated with ExoQuick exosome precipitation solution (System Biosciences, Inc., Mountainview, CA), and the resultant suspensions were centrifuged
for 30 min at 1500g at 4°C. Each pellet was resuspended
in 300 lL of distilled water with inhibitor cocktails for
immunochemical enrichment of exosomes from neuronal
sources.7
Exosome suspensions were incubated with 2 lg of
mouse anti-human CD171 (L1CAM neural adhesion protein) biotinylated antibody (clone 5G3, eBioscience, San
Diego, CA) in 50 lL of 3% BSA for 60 min at 20°C followed by addition of 10 lL of Streptavidin-Plus UltraLink
resin (Pierce-Thermo Scientific, Inc.) in 40 lL of 3%
BSA.7 After incubation for 30 min at 20°C, centrifugation
at 400g for 5 min at 4°C, and removal of supernatants,
pellets were resuspended in 50 lL of 0.05 mol/L glycineHCl (pH 3.0), incubated 10 min at 4°C, and recentrifuged for 10 min at 4000g at 4°C. Each supernatant in
a new Eppendorf tube received 5 lL of 1 mol/L Tris-HCl
(pH 8.0) and 45 lL of 3% BSA followed by 0.40 mL of
mammalian protein extraction reagent (Thermo Scientific,
Inc.) containing protease and phosphatase inhibitors,
mixed and stored at 80°C.
Exosome proteins were quantified by human-specific
ELISAs for Ab1-42, P-S396-tau (Life Technologies/Invitrogen, Camarillo, CA), P-T181-tau (Innogenetics Division
of Fujirebio US, Inc., Alpharetta, GA), REST (Cusabio,
American Research Products, Inc., Waltham, MA), neurogranin (Cloud-Clone, Inc., American Research Products,
Inc.), cathepsin D (EMD Millipore Corp., Billerica, MA),
and tetraspanin exosome marker human CD81 (American
Research Products-Cusabio), according to the suppliers’
directions. One in ten representative preparations of exosomes was counted and CD63 levels were determined
along with CD81. The mean value for all determinations
of CD81 in each assay group was set at 1.00 and the relative values for each sample used to normalize their recovery. Units for all analytes are pg/neuronal-derived
exosomes in 1 mL of plasma (pg/ml). Ab1-42 and P-S396tau in exosome extracts were quantified at a 1:2 (v:v)
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dilution, whereas CD81, P-T181-tau, REST, and cathepsin
D were quantified at a 1:4 (v:v) dilution. Evidence for
enrichment of exosomes from neuronal sources has been
provided previously.7,13

Statistical analyses
We used paired t tests to estimate mean change in protein levels over time, and we used linear regression to
estimate mean P-T181-tau, P-S-396-tau, Ab1-42, cathepsin D, REST, and neurogranin levels at the first draw
using age at draw as the predictor. Next, we regressed
the change score on age at first draw and time between
draws (years). Last, we compared protein levels at the
second draw to distributions obtained from 10 age- and
sex-matched AD patients for overlap. Plasma from AD
patients was obtained from the National Institute on
Aging plasma bank; AD diagnosis was made by neurological exam, psychometric testing, CSF protein analytes,
and MRI using standard criteria.13 All analyses were
conducted with SAS 9.4 (SAS Institute, Inc.; Cary,
NC).

Results
Median time between draws was 8.7 years (range 3.3–
11.4), and all but four pairs occurred at least 7 years
apart. Mini-Mental State Examination14 scores decreased
slightly over the interval (P = 0.049; Table 1). Paired t
tests showed that P-T181-tau (P = 0.0047), Ab1-42
(P = 0.014), cathepsin D (P = 0.0022), and REST
(P = 0.0078) increased over time (Table 2). Neurogranin
decreased (P < 0.0001) and P-S396-tau (P = 0.57) did
not change. Regression revealed significant association
between P-S396-tau change and age at first draw
(P = 0.024), with older participants experiencing larger
increases. However, significance did not persist (P = 0.31)
after excluding the oldest participant (age 92), who also
had the largest increase in P-S396-tau level. This participant was diagnosed with probable AD 2 years following
the second blood draw. No other change scores were
associated significantly with age at first draw or time
between draws. Analyses were repeated excluding participants with draws less than 7 years apart. Results were
similar and conclusions did not change.
Cathepsin D, REST, and neurogranin levels in CIS were
distinct from those of AD patients (Fig. 1). There was frequent overlap between CIS and AD patients for Ab1-42
levels (6/20) and less frequent for P-T181-tau (1/20) and
P-S396-tau (2/20) (Fig. 1). In comparison, some participants also had CSF protein levels in the AD range15: CSF
Ab1-42 (2/20; <192 pg/mL), total tau (1/20; >93 pg/mL),
and P-T181-tau (10/20; >23 pg/mL).
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Table 1. Sample characteristics of cognitively intact University of
Kentucky Alzheimer’s Disease Center research volunteers1.

Characteristic

First
draw (n = 18)

Second draw
(n = 20)

Age, y
Education, y
Female (%)
White race (%)
Mini-mental state examination
APOE-e4 carriers (n)
CSF Ab1-42 (pg/mL)
CSF P-T181-tau (pg/mL)
CSF total tau (pg/mL)

69.3 (5.6)
16.3 (2.5)
55.6
100
29.7 (0.5)
3
n/a
n/a
n/a

77.6
16.3
50.0
100
29.4
3
300.1
23.9
57.3

(6.1)2
(2.5)

(0.8)2
(76.9)
(8.4)
(17.3)

CSF, cerebrospinal fluid.
Results presented are mean (SD).
2
Significant change from first draw by paired t test (P < 0.05).
1

Table 2. Mean normalized protein levels (pg/mL) in plasma neuronalderived exosomes.1

P-T181 tau
P-S396 tau
Ab1-42
Cathepsin D
REST
Neurogranin

First draw
(n = 18)

Second draw
(n = 20)

73.4
10.9
2.9
1972.4
906.4
285.1

88.2
11.4
3.8
4074.6
1437.0
224.8

(25.3)
(5.1)2
(1.3)
(1382.0)
(503.0)
(76.8)

(22.7)3
(4.3)
(1.9)3
(2117.4)3
(720.0)3
(61.0)3

1

Results presented are mean (SD).
Protein level at first draw was significantly associated with age at first
draw. Significance did not persist after excluding the oldest participant.
3
Significant change from first draw by paired t test (P < 0.05).
2

Discussion
This study provides evidence that neuronally derived exosome proteins Ab1-42, P-T181-tau, REST, and cathepsin D
in older CIS increase over 3–11 years, whereas neurogranin decreases and P-S396-tau changes little over the
same interval. Despite these changes, levels of REST,
cathepsin D, and neurogranin were distinct from the
ranges associated with AD. Importantly, we showed that
levels of the neuroprotection factor REST, measured in
plasma neuronal exosomes, increased with normal aging,
similar to what has been shown in human brain tissue.16
We also reported results of the first analyses of neurogranin in plasma neuronal exosomes; results were similar
to the decreased levels seen in human brain tissue7 in
contrast to increases in CSF concentrations with aging
and dementia.9,10 This study further establishes the distinctive natures of the CSF and exosomal pathways for
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Figure 1. Levels of plasma exosomal proteins in age- and sex-matched cognitively intact subjects (CIS) and patients with Alzheimer’s disease(AD).

exportation from CNS neurons of proteins relevant to the
pathogenesis of dementias.
Changes in established AD biomarkers, Ab1-42, P-T181tau, and P-S396-tau, moved some levels for CIS into the
range of measurements observed in AD patients, as has
been observed with CSF analytes. Overlap may represent
variability in the distribution of values but may also identify participants at increased risk for future AD diagnosis.17 Indeed, for the CIS who transitioned to Probable
AD 2 years after the second draw, protein levels were in
the AD range for both Ab1-42 (6.4 pg/mL) and P-S396tau (22.4 pg/mL). Basic conclusions, except for the significance of P-S396-tau age associations, were not altered as
a result of repeating statistical analyses excluding this
participant.
Our data demonstrated that normal aging is associated
with increases in certain AD biomarkers. Based on our
prior work, preclinical AD cases may show mean protein
levels similar to CIS on measures like Ab1-42, P-S396-tau,
and P-T181-tau, although the upper range of measurement tends to be lower in CIS.5 In comparison, REST
and cathepsin D levels may be completely distinct in preclinical AD and CIS.6,7 Future determination of thresholds for transition from normal aging to AD is critically
important for interpretation of such biomarkers including
Ab1-42, P-T181-tau, REST, cathepsin D, and neurogranin.
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In contrast, P-S396-tau appears to exhibit distinctive
specificity for the diagnosis of imminent or fulminant
AD. This is consistent with our previous work demonstrating a lack of P-S396-tau elevations in FTD, and
nonoverlapping P-S396-tau levels in controls who did not
progress to AD over a 10-year period compared to those
with AD and those who eventually developed AD.5 The
specificity of the antemortem CSF level of P-S396-tau epitope for fulminant AD or AD in situ with imminent clinical presentation has been published previously and
parallels our findings in exosomes,18 which represent a
less invasive, peripheral blood-derived biomarker. While
the utility of exosomal P-S396-tau for detection of fulminant AD appears consistent across studies, we note that
this biomarker may lack diagnostic utility prior to the
imminent development of symptomatic AD. Further
research should address the temporal course of exosomal
epitope changes heralding the onset of AD and the establishment of diagnostic thresholds for exosomal markers of
preclinical AD.
Our findings add important information to existing literature on neuronally derived exosome-based biomarkers,
but there are limitations in interpretation. Although the
participants are well-characterized clinically, sample size is
limited and may not be representative of the larger population of CIS. Additional participants may transition to
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AD in the future. Replication studies are needed to confirm our results.
6.
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